Cyclo Therapeutics, Inc. (CYTH) Stock Competitors & Peer Comparison
See (CYTH) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CYTH | $0.72 | +0.00% | 23.6M | -0.80 | -$0.90 | N/A |
| TAK | $15.03 | -0.99% | 47.5B | 39.58 | $0.38 | +4.14% |
| HLN | $8.72 | +0.23% | 38.7B | 17.43 | $0.50 | +2.22% |
| TEVA | $32.83 | -0.76% | 38.2B | 24.50 | $1.34 | N/A |
| VTRS | $15.56 | -0.83% | 18.1B | -51.87 | -$0.30 | +3.09% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.57 | +3.98% | 12.3B | -49.16 | -$0.50 | N/A |
| RGC | $23.75 | +2.59% | 11.7B | -2375.00 | -$0.01 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.02 | -0.08% | 10.8B | 24.12 | $0.54 | +0.70% |
Stock Comparison
CYTH vs TAK Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TAK has a market cap of 47.5B. Regarding current trading prices, CYTH is priced at $0.72, while TAK trades at $15.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TAK's P/E ratio is 39.58. In terms of profitability, CYTH's ROE is -7.30%, compared to TAK's ROE of +0.03%. Regarding short-term risk, CYTH is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TAK's competition here
CYTH vs HLN Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, HLN has a market cap of 38.7B. Regarding current trading prices, CYTH is priced at $0.72, while HLN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas HLN's P/E ratio is 17.43. In terms of profitability, CYTH's ROE is -7.30%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HLN's competition here
CYTH vs TEVA Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TEVA has a market cap of 38.2B. Regarding current trading prices, CYTH is priced at $0.72, while TEVA trades at $32.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TEVA's P/E ratio is 24.50. In terms of profitability, CYTH's ROE is -7.30%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, CYTH is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TEVA's competition here
CYTH vs VTRS Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, VTRS has a market cap of 18.1B. Regarding current trading prices, CYTH is priced at $0.72, while VTRS trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas VTRS's P/E ratio is -51.87. In terms of profitability, CYTH's ROE is -7.30%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, CYTH is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check VTRS's competition here
CYTH vs ITCI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CYTH is priced at $0.72, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CYTH's ROE is -7.30%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CYTH and ITCI have similar daily volatility (0.00).Check ITCI's competition here
CYTH vs ELAN Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ELAN has a market cap of 12.3B. Regarding current trading prices, CYTH is priced at $0.72, while ELAN trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ELAN's P/E ratio is -49.16. In terms of profitability, CYTH's ROE is -7.30%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, CYTH is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ELAN's competition here
CYTH vs RGC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, RGC has a market cap of 11.7B. Regarding current trading prices, CYTH is priced at $0.72, while RGC trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas RGC's P/E ratio is -2375.00. In terms of profitability, CYTH's ROE is -7.30%, compared to RGC's ROE of -2.32%. Regarding short-term risk, CYTH is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RGC's competition here
CYTH vs CTLT Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CYTH is priced at $0.72, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CYTH's ROE is -7.30%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CYTH is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CTLT's competition here
CYTH vs RDY Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, RDY has a market cap of 10.8B. Regarding current trading prices, CYTH is priced at $0.72, while RDY trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas RDY's P/E ratio is 24.12. In terms of profitability, CYTH's ROE is -7.30%, compared to RDY's ROE of +0.12%. Regarding short-term risk, CYTH is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RDY's competition here
CYTH vs LNTH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, CYTH is priced at $0.72, while LNTH trades at $100.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas LNTH's P/E ratio is 23.93. In terms of profitability, CYTH's ROE is -7.30%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, CYTH is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LNTH's competition here
CYTH vs INDV Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, CYTH is priced at $0.72, while INDV trades at $35.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas INDV's P/E ratio is 18.17. In terms of profitability, CYTH's ROE is -7.30%, compared to INDV's ROE of -1.42%. Regarding short-term risk, CYTH is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check INDV's competition here
CYTH vs AMRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AMRX has a market cap of 4.1B. Regarding current trading prices, CYTH is priced at $0.72, while AMRX trades at $12.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AMRX's P/E ratio is 34.80. In terms of profitability, CYTH's ROE is -7.30%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, CYTH is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AMRX's competition here
CYTH vs SUPN Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, CYTH is priced at $0.72, while SUPN trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SUPN's P/E ratio is -86.34. In terms of profitability, CYTH's ROE is -7.30%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, CYTH is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SUPN's competition here
CYTH vs DCPH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CYTH is priced at $0.72, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CYTH's ROE is -7.30%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CYTH is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check DCPH's competition here
CYTH vs AVDL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CYTH is priced at $0.72, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CYTH's ROE is -7.30%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, CYTH and AVDL have similar daily volatility (0.00).Check AVDL's competition here
CYTH vs HCM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, HCM has a market cap of 2B. Regarding current trading prices, CYTH is priced at $0.72, while HCM trades at $11.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas HCM's P/E ratio is 4.27. In terms of profitability, CYTH's ROE is -7.30%, compared to HCM's ROE of +0.41%. Regarding short-term risk, CYTH is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HCM's competition here
CYTH vs EMBCV Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CYTH is priced at $0.72, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, CYTH is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EMBCV's competition here
CYTH vs BHC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, CYTH is priced at $0.72, while BHC trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas BHC's P/E ratio is -1.53. In terms of profitability, CYTH's ROE is -7.30%, compared to BHC's ROE of +1.21%. Regarding short-term risk, CYTH is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BHC's competition here
CYTH vs DVAX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CYTH is priced at $0.72, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CYTH's ROE is -7.30%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, CYTH and DVAX have similar daily volatility (0.00).Check DVAX's competition here
CYTH vs ANIP Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, CYTH is priced at $0.72, while ANIP trades at $75.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ANIP's P/E ratio is 19.24. In terms of profitability, CYTH's ROE is -7.30%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ANIP's competition here
CYTH vs TARO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CYTH is priced at $0.72, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TARO's P/E ratio is 30.05. In terms of profitability, CYTH's ROE is -7.30%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CYTH is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TARO's competition here
CYTH vs PRGO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, CYTH is priced at $0.72, while PRGO trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PRGO's P/E ratio is -0.81. In terms of profitability, CYTH's ROE is -7.30%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, CYTH is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PRGO's competition here
CYTH vs PAHC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, CYTH is priced at $0.72, while PAHC trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PAHC's P/E ratio is 13.64. In terms of profitability, CYTH's ROE is -7.30%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, CYTH is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PAHC's competition here
CYTH vs HROW Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, CYTH is priced at $0.72, while HROW trades at $33.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas HROW's P/E ratio is -87.68. In terms of profitability, CYTH's ROE is -7.30%, compared to HROW's ROE of -0.34%. Regarding short-term risk, CYTH is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HROW's competition here
CYTH vs EVO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EVO has a market cap of 1B. Regarding current trading prices, CYTH is priced at $0.72, while EVO trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EVO's P/E ratio is -4.59. In terms of profitability, CYTH's ROE is -7.30%, compared to EVO's ROE of -0.24%. Regarding short-term risk, CYTH is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EVO's competition here
CYTH vs CRON Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, CYTH is priced at $0.72, while CRON trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CRON's P/E ratio is -135.50. In terms of profitability, CYTH's ROE is -7.30%, compared to CRON's ROE of -0.00%. Regarding short-term risk, CYTH is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CRON's competition here
CYTH vs COLL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, COLL has a market cap of 1B. Regarding current trading prices, CYTH is priced at $0.72, while COLL trades at $31.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas COLL's P/E ratio is 15.08. In terms of profitability, CYTH's ROE is -7.30%, compared to COLL's ROE of +0.27%. Regarding short-term risk, CYTH is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check COLL's competition here
CYTH vs ALVO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALVO has a market cap of 979.8M. Regarding current trading prices, CYTH is priced at $0.72, while ALVO trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ALVO's P/E ratio is 31.40. In terms of profitability, CYTH's ROE is -7.30%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, CYTH is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALVO's competition here
CYTH vs PETQ Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CYTH is priced at $0.72, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CYTH's ROE is -7.30%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CYTH is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PETQ's competition here
CYTH vs PCRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PCRX has a market cap of 878M. Regarding current trading prices, CYTH is priced at $0.72, while PCRX trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PCRX's P/E ratio is 171.69. In terms of profitability, CYTH's ROE is -7.30%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, CYTH is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PCRX's competition here
CYTH vs AMPH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AMPH has a market cap of 799M. Regarding current trading prices, CYTH is priced at $0.72, while AMPH trades at $18.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AMPH's P/E ratio is 10.92. In terms of profitability, CYTH's ROE is -7.30%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, CYTH is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AMPH's competition here
CYTH vs TLRY Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TLRY has a market cap of 611.2M. Regarding current trading prices, CYTH is priced at $0.72, while TLRY trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TLRY's P/E ratio is -0.35. In terms of profitability, CYTH's ROE is -7.30%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, CYTH is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TLRY's competition here
CYTH vs BDSI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CYTH is priced at $0.72, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CYTH's ROE is -7.30%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CYTH is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BDSI's competition here
CYTH vs IRWD Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, IRWD has a market cap of 533.3M. Regarding current trading prices, CYTH is priced at $0.72, while IRWD trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas IRWD's P/E ratio is 5.23. In terms of profitability, CYTH's ROE is -7.30%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, CYTH is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check IRWD's competition here
CYTH vs CGC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CGC has a market cap of 442.9M. Regarding current trading prices, CYTH is priced at $0.72, while CGC trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CGC's P/E ratio is -0.77. In terms of profitability, CYTH's ROE is -7.30%, compared to CGC's ROE of -0.51%. Regarding short-term risk, CYTH is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CGC's competition here
CYTH vs KMDA Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, KMDA has a market cap of 426.3M. Regarding current trading prices, CYTH is priced at $0.72, while KMDA trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas KMDA's P/E ratio is 21.11. In terms of profitability, CYTH's ROE is -7.30%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CYTH is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check KMDA's competition here
CYTH vs AQST Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AQST has a market cap of 400.2M. Regarding current trading prices, CYTH is priced at $0.72, while AQST trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AQST's P/E ratio is -6.61. In terms of profitability, CYTH's ROE is -7.30%, compared to AQST's ROE of +1.91%. Regarding short-term risk, CYTH is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AQST's competition here
CYTH vs EOLS Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EOLS has a market cap of 397.1M. Regarding current trading prices, CYTH is priced at $0.72, while EOLS trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EOLS's P/E ratio is -9.14. In terms of profitability, CYTH's ROE is -7.30%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, CYTH is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EOLS's competition here
CYTH vs SNDL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SNDL has a market cap of 365.5M. Regarding current trading prices, CYTH is priced at $0.72, while SNDL trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SNDL's P/E ratio is -47.00. In terms of profitability, CYTH's ROE is -7.30%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, CYTH is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SNDL's competition here
CYTH vs SIGA Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SIGA has a market cap of 307.7M. Regarding current trading prices, CYTH is priced at $0.72, while SIGA trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SIGA's P/E ratio is 15.32. In terms of profitability, CYTH's ROE is -7.30%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, CYTH is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SIGA's competition here
CYTH vs ALIM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CYTH is priced at $0.72, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CYTH's ROE is -7.30%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CYTH is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALIM's competition here
CYTH vs ORGO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ORGO has a market cap of 299.8M. Regarding current trading prices, CYTH is priced at $0.72, while ORGO trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ORGO's P/E ratio is -19.42. In terms of profitability, CYTH's ROE is -7.30%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, CYTH is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ORGO's competition here
CYTH vs TKNO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TKNO has a market cap of 275M. Regarding current trading prices, CYTH is priced at $0.72, while TKNO trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TKNO's P/E ratio is -16.55. In terms of profitability, CYTH's ROE is -7.30%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, CYTH is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TKNO's competition here
CYTH vs LNDC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CYTH is priced at $0.72, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CYTH's ROE is -7.30%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, CYTH is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LNDC's competition here
CYTH vs TYHT Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CYTH is priced at $0.72, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CYTH's ROE is -7.30%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, CYTH is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TYHT's competition here
CYTH vs LFCR Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, LFCR has a market cap of 212.7M. Regarding current trading prices, CYTH is priced at $0.72, while LFCR trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas LFCR's P/E ratio is -4.46. In terms of profitability, CYTH's ROE is -7.30%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, CYTH is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LFCR's competition here
CYTH vs EMBC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EMBC has a market cap of 197M. Regarding current trading prices, CYTH is priced at $0.72, while EMBC trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EMBC's P/E ratio is 1.76. In terms of profitability, CYTH's ROE is -7.30%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, CYTH is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EMBC's competition here
CYTH vs ACB Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ACB has a market cap of 193.9M. Regarding current trading prices, CYTH is priced at $0.72, while ACB trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ACB's P/E ratio is -3.17. In terms of profitability, CYTH's ROE is -7.30%, compared to ACB's ROE of -0.08%. Regarding short-term risk, CYTH is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ACB's competition here
CYTH vs REPH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CYTH is priced at $0.72, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas REPH's P/E ratio is -8.04. In terms of profitability, CYTH's ROE is -7.30%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CYTH is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check REPH's competition here
CYTH vs DERM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, DERM has a market cap of 166.8M. Regarding current trading prices, CYTH is priced at $0.72, while DERM trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas DERM's P/E ratio is -16.38. In terms of profitability, CYTH's ROE is -7.30%, compared to DERM's ROE of -0.36%. Regarding short-term risk, CYTH is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check DERM's competition here
CYTH vs THTX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CYTH is priced at $0.72, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas THTX's P/E ratio is -17.84. In terms of profitability, CYTH's ROE is -7.30%, compared to THTX's ROE of +0.47%. Regarding short-term risk, CYTH is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check THTX's competition here
CYTH vs ASRT Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ASRT has a market cap of 151.7M. Regarding current trading prices, CYTH is priced at $0.72, while ASRT trades at $23.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ASRT's P/E ratio is -4.23. In terms of profitability, CYTH's ROE is -7.30%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CYTH is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ASRT's competition here
CYTH vs OGI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, OGI has a market cap of 149.2M. Regarding current trading prices, CYTH is priced at $0.72, while OGI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas OGI's P/E ratio is -6.62. In terms of profitability, CYTH's ROE is -7.30%, compared to OGI's ROE of -0.07%. Regarding short-term risk, CYTH is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check OGI's competition here
CYTH vs CRDL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CRDL has a market cap of 125.3M. Regarding current trading prices, CYTH is priced at $0.72, while CRDL trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CRDL's P/E ratio is -4.00. In terms of profitability, CYTH's ROE is -7.30%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, CYTH is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CRDL's competition here
CYTH vs SCTL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CYTH is priced at $0.72, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CYTH's ROE is -7.30%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CYTH is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SCTL's competition here
CYTH vs PROC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CYTH is priced at $0.72, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PROC's P/E ratio is 1.53. In terms of profitability, CYTH's ROE is -7.30%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CYTH and PROC have similar daily volatility (0.00).Check PROC's competition here
CYTH vs OPTN Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CYTH is priced at $0.72, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CYTH's ROE is -7.30%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, CYTH and OPTN have similar daily volatility (0.00).Check OPTN's competition here
CYTH vs ZOM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CYTH is priced at $0.72, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CYTH's ROE is -7.30%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, CYTH is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZOM's competition here
CYTH vs GRVI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CYTH is priced at $0.72, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CYTH's ROE is -7.30%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, CYTH is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check GRVI's competition here
CYTH vs CPIX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CPIX has a market cap of 84.1M. Regarding current trading prices, CYTH is priced at $0.72, while CPIX trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CPIX's P/E ratio is -11.45. In terms of profitability, CYTH's ROE is -7.30%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, CYTH is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CPIX's competition here
CYTH vs ZYNE Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CYTH is priced at $0.72, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CYTH's ROE is -7.30%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CYTH is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZYNE's competition here
CYTH vs SSIC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CYTH is priced at $0.72, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CYTH's ROE is -7.30%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CYTH is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SSIC's competition here
CYTH vs ALVOW Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALVOW has a market cap of 62.1M. Regarding current trading prices, CYTH is priced at $0.72, while ALVOW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ALVOW's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, CYTH is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALVOW's competition here
CYTH vs VLNS Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CYTH is priced at $0.72, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CYTH's ROE is -7.30%, compared to VLNS's ROE of N/A. Regarding short-term risk, CYTH is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check VLNS's competition here
CYTH vs DRRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CYTH is priced at $0.72, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CYTH's ROE is -7.30%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, CYTH and DRRX have similar daily volatility (0.00).Check DRRX's competition here
CYTH vs BGM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, BGM has a market cap of 58.2M. Regarding current trading prices, CYTH is priced at $0.72, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas BGM's P/E ratio is -1.00. In terms of profitability, CYTH's ROE is -7.30%, compared to BGM's ROE of -0.03%. Regarding short-term risk, CYTH is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BGM's competition here
CYTH vs INCR Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, INCR has a market cap of 56.9M. Regarding current trading prices, CYTH is priced at $0.72, while INCR trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas INCR's P/E ratio is -4.52. In terms of profitability, CYTH's ROE is -7.30%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CYTH is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check INCR's competition here
CYTH vs JUPW Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CYTH is priced at $0.72, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CYTH's ROE is -7.30%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, CYTH is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check JUPW's competition here
CYTH vs QLI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CYTH is priced at $0.72, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas QLI's P/E ratio is -4.92. In terms of profitability, CYTH's ROE is -7.30%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CYTH and QLI have similar daily volatility (0.00).Check QLI's competition here
CYTH vs ZYBT Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZYBT has a market cap of 37.7M. Regarding current trading prices, CYTH is priced at $0.72, while ZYBT trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ZYBT's P/E ratio is -3.61. In terms of profitability, CYTH's ROE is -7.30%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, CYTH is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZYBT's competition here
CYTH vs IXHL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, IXHL has a market cap of 35.1M. Regarding current trading prices, CYTH is priced at $0.72, while IXHL trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas IXHL's P/E ratio is -0.18. In terms of profitability, CYTH's ROE is -7.30%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, CYTH is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check IXHL's competition here
CYTH vs HEXO Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CYTH is priced at $0.72, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CYTH's ROE is -7.30%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CYTH is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HEXO's competition here
CYTH vs SCYX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SCYX has a market cap of 29.4M. Regarding current trading prices, CYTH is priced at $0.72, while SCYX trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SCYX's P/E ratio is -1.22. In terms of profitability, CYTH's ROE is -7.30%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, CYTH is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SCYX's competition here
CYTH vs RMTI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, RMTI has a market cap of 26.7M. Regarding current trading prices, CYTH is priced at $0.72, while RMTI trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas RMTI's P/E ratio is -4.50. In terms of profitability, CYTH's ROE is -7.30%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, CYTH is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RMTI's competition here
CYTH vs TXMD Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TXMD has a market cap of 22.8M. Regarding current trading prices, CYTH is priced at $0.72, while TXMD trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TXMD's P/E ratio is 197.00. In terms of profitability, CYTH's ROE is -7.30%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, CYTH is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TXMD's competition here
CYTH vs QNTM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, QNTM has a market cap of 21.9M. Regarding current trading prices, CYTH is priced at $0.72, while QNTM trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas QNTM's P/E ratio is -0.63. In terms of profitability, CYTH's ROE is -7.30%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, CYTH is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check QNTM's competition here
CYTH vs EVOK Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CYTH is priced at $0.72, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CYTH's ROE is -7.30%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, CYTH and EVOK have similar daily volatility (0.00).Check EVOK's competition here
CYTH vs OPTH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, OPTH has a market cap of 18.3M. Regarding current trading prices, CYTH is priced at $0.72, while OPTH trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas OPTH's P/E ratio is -5.20. In terms of profitability, CYTH's ROE is -7.30%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, CYTH is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check OPTH's competition here
CYTH vs AYTU Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AYTU has a market cap of 16.9M. Regarding current trading prices, CYTH is priced at $0.72, while AYTU trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AYTU's P/E ratio is -0.45. In terms of profitability, CYTH's ROE is -7.30%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, CYTH is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AYTU's competition here
CYTH vs TLPH Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, TLPH has a market cap of 15.7M. Regarding current trading prices, CYTH is priced at $0.72, while TLPH trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas TLPH's P/E ratio is -2.73. In terms of profitability, CYTH's ROE is -7.30%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, CYTH is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TLPH's competition here
CYTH vs ACRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CYTH is priced at $0.72, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CYTH's ROE is -7.30%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, CYTH is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ACRX's competition here
CYTH vs COSM Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, COSM has a market cap of 13.4M. Regarding current trading prices, CYTH is priced at $0.72, while COSM trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas COSM's P/E ratio is -0.37. In terms of profitability, CYTH's ROE is -7.30%, compared to COSM's ROE of -0.96%. Regarding short-term risk, CYTH is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check COSM's competition here
CYTH vs BFRI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, BFRI has a market cap of 12.6M. Regarding current trading prices, CYTH is priced at $0.72, while BFRI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas BFRI's P/E ratio is -1.01. In terms of profitability, CYTH's ROE is -7.30%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, CYTH is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BFRI's competition here
CYTH vs AGRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CYTH is priced at $0.72, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CYTH's ROE is -7.30%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CYTH is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AGRX's competition here
CYTH vs NLTX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CYTH is priced at $0.72, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CYTH's ROE is -7.30%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, CYTH is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check NLTX's competition here
CYTH vs LCI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CYTH is priced at $0.72, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas LCI's P/E ratio is -0.04. In terms of profitability, CYTH's ROE is -7.30%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CYTH is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LCI's competition here
CYTH vs YCBD Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, YCBD has a market cap of 7.3M. Regarding current trading prices, CYTH is priced at $0.72, while YCBD trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas YCBD's P/E ratio is 0.28. In terms of profitability, CYTH's ROE is -7.30%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CYTH is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check YCBD's competition here
CYTH vs BGXX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, CYTH is priced at $0.72, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas BGXX's P/E ratio is -0.76. In terms of profitability, CYTH's ROE is -7.30%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, CYTH and BGXX have similar daily volatility (0.00).Check BGXX's competition here
CYTH vs ADMP Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CYTH is priced at $0.72, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CYTH's ROE is -7.30%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CYTH is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ADMP's competition here
CYTH vs EGRX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, EGRX has a market cap of 6.1M. Regarding current trading prices, CYTH is priced at $0.72, while EGRX trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas EGRX's P/E ratio is 6.57. In terms of profitability, CYTH's ROE is -7.30%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EGRX's competition here
CYTH vs MNK Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CYTH is priced at $0.72, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas MNK's P/E ratio is -0.44. In terms of profitability, CYTH's ROE is -7.30%, compared to MNK's ROE of -0.26%. Regarding short-term risk, CYTH is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check MNK's competition here
CYTH vs GELS Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, CYTH is priced at $0.72, while GELS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas GELS's P/E ratio is -0.93. In terms of profitability, CYTH's ROE is -7.30%, compared to GELS's ROE of -0.43%. Regarding short-term risk, CYTH is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check GELS's competition here
CYTH vs FLGC Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CYTH is priced at $0.72, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CYTH's ROE is -7.30%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, CYTH is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check FLGC's competition here
CYTH vs GHSI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, CYTH is priced at $0.72, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas GHSI's P/E ratio is -0.79. In terms of profitability, CYTH's ROE is -7.30%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, CYTH and GHSI have similar daily volatility (0.00).Check GHSI's competition here
CYTH vs RDHL Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, RDHL has a market cap of 3.1M. Regarding current trading prices, CYTH is priced at $0.72, while RDHL trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas RDHL's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, CYTH is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RDHL's competition here
CYTH vs CPHI Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, CPHI has a market cap of 2.8M. Regarding current trading prices, CYTH is priced at $0.72, while CPHI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas CPHI's P/E ratio is -1.61. In terms of profitability, CYTH's ROE is -7.30%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, CYTH is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CPHI's competition here
CYTH vs PLXP Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CYTH is priced at $0.72, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CYTH's ROE is -7.30%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CYTH is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PLXP's competition here
CYTH vs ATNX Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CYTH is priced at $0.72, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CYTH's ROE is -7.30%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CYTH and ATNX have similar daily volatility (0.00).Check ATNX's competition here
CYTH vs SNOA Comparison June 2026
CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTH stands at 23.6M. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, CYTH is priced at $0.72, while SNOA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTH currently has a P/E ratio of -0.80, whereas SNOA's P/E ratio is -0.62. In terms of profitability, CYTH's ROE is -7.30%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, CYTH is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SNOA's competition here